We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Genetic Clues Link Lipoprotein A to Prostate Cancer Risk

By LabMedica International staff writers
Posted on 07 Feb 2022
Print article
Image: Histopathology of adenocarcinoma of the prostate on needle biopsy consisting of small glands with amphophilic cytoplasm (Photo courtesy of Professor Jonathan I. Epstein, MD)
Image: Histopathology of adenocarcinoma of the prostate on needle biopsy consisting of small glands with amphophilic cytoplasm (Photo courtesy of Professor Jonathan I. Epstein, MD)

Some factors associated with higher risk of prostate cancer (PCa) cannot be modified, such as older age and being of African descent. Meanwhile, other risk factors for the aggressive form of the disease, such as smoking and obesity, can potentially be modified.

Lipid-lowering therapies are cheap and well established for lowering cardiovascular risk. Yet, there is no conclusive evidence that repurposed lipid-lowering drugs are effective for the prevention of PCa. It is therefore important to determine whether blood lipids increase PCa risk, especially lethal disease,

An international team that included Cancer Epidemiologists and led by those at the Imperial College London (London, UK) analyzed links between prostate cancer risk and several blood lipids: namely, lipoprotein A (Lp(a), low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, and apolipoproteins A and B.

The study employed a method known as Mendelian randomization, which harnesses the inherent randomness of the genetic process of meiosis to boost the validity of an analysis. So, instead of considering direct measurements of lipids in the bloodstream, the team evaluated variations in individuals’ DNA sequences that are associated with different blood levels of the lipids. Then, they analyzed if these genetic variants were statistically linked to prostate cancer risk.

The investigators reported that their analysis showed that genetic variants that predict higher blood levels of lipoprotein A were associated with a higher overall risk of prostate cancer, and also a higher risk of advanced or early-age-onset prostate cancer. They did not find any significant associations for any of the other blood lipids. These findings suggest the possibility that lipoprotein A-lowering drugs could be developed or repurposed to lower risk of prostate cancer for some individuals.

The authors concluded that their findings from this study point towards a positive association between genetically predicted Lp(a) concentrations and risk of total, advanced, and early age onset PCa. Screening for high Lp(a) concentrations could possibly be investigated in the future to identify high-risk groups for PCa. Given that Lp(a) concentrations depend significantly on genetics, modification of Lp(a) levels may be achieved by developing Lp(a)-lowering drugs that might be on the horizon. The study was published on January 27, 2022 in the journal PLOS Medicine.

Related Links:
Imperial College London 

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
H.pylori Test
Humasis H.pylori Card
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.